Načítá se...
Therapeutic Targeting of RAS: New Hope for Drugging the “Undruggable”
RAS is the most frequently mutated oncogene in cancer and a critical driver of oncogenesis. Therapeutic targeting of RAS has been a goal of cancer research for more than 30 years due to its essential role in tumor formation and maintenance. Yet the quest to inhibit this challenging foe has been elus...
Uloženo v:
| Vydáno v: | Biochim Biophys Acta Mol Cell Res |
|---|---|
| Hlavní autoři: | , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
2019
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6937383/ https://ncbi.nlm.nih.gov/pubmed/31678118 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.bbamcr.2019.118570 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|